Adial Pharmaceuticals, Inc. (AZR) shareholders
Close on Nov 17, 2026Market cap $9.62MP/E –Yield –
Ownership
Who owns Adial Pharmaceuticals's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Coastlands Capital LP Joint filing with Coastlands Capital Partners LP (14.22%), Coastlands Capital GP LLC (14.22%) and 2 more | 373,322 | 14.22% | 13G (passive) amendment | Jun 24, 2026 |
| Coastlands Capital LLC Joint filing with Coastlands Capital LP (9.98%), Coastlands Capital Partners LP (9.98%) and 2 more | 262,167 | 9.98% | 13G (passive) | Jun 17, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matt Davidson | President and CEO, Director | 923,743 | 35.18% | Nov 4, 2026 |
| Tony Goodman | Chief Operating Officer, Director | 26,523 | 1.01% | Apr 9, 2026 |
| Cary J. Claiborne | Chief Executive Officer, Director | 40,417 | 1.54% | Apr 9, 2026 |
| Julie Saiki | Chief Strategy Officer | 761,636 | 29.00% | Nov 4, 2026 |
| Vassiliki Economides | Chief Financial Officer | – | – | Oct 30, 2026 |
| Vinay Shah | Chief Financial Officer | 17,325 | 0.66% | Apr 9, 2026 |
| Aida Habtezion | Director | – | – | Nov 10, 2026 |
| Paul J. Hastings | Director | – | – | Nov 10, 2026 |
| Thomas M. Soloway | Director | – | – | Nov 10, 2026 |
| Wendy B. Young | Director | – | – | Sep 21, 2026 |
| Kevin Schuyler | Director | 9,447 | 0.36% | Apr 9, 2026 |
| J. Kermit Anderson | Director | – | – | Apr 9, 2026 |
| Robertson H. Gilliland | Director | 104,609 | 3.98% | Apr 9, 2026 |
| James W. Newman Jr. | Director | 338,463 | 12.89% | Jun 2, 2025 |
| Capital LP Coastlands | 10% owner | 388,308 | 14.79% | Nov 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matt Davidson President and CEO, Director | Nov 2, 2026 | Conversion | +101,298 | – | – | 104,725 |
| Matt Davidson President and CEO, Director | Nov 2, 2026 | Conversion | +524,954 | – | – | 819,018 |
| Julie Saiki Chief Strategy Officer | Nov 2, 2026 | Conversion | +626,252 | – | – | 761,636 |
| Matt Davidson President and CEO, Director | Oct 28, 2026 | Award | +232,417 | – | – | 294,064 |
| Capital LP Coastlands 10% owner | Jul 16, 2026 | Buy | +1,233 | $2.75 | $3.39K | 388,308 |
| Capital LP Coastlands 10% owner | Jul 14, 2026 | Buy | +2,000 | $2.65 | $5.30K | 387,075 |
| Capital LP Coastlands 10% owner | Jul 10, 2026 | Buy | +1,700 | $2.70 | $4.59K | 385,075 |
| Capital LP Coastlands 10% owner | Jul 9, 2026 | Buy | +10,053 | $2.79 | $28.05K | 383,375 |
| Capital LP Coastlands 10% owner | Jun 29, 2026 | Buy | +25,000 | $2.60 | $65.00K | 373,322 |
| Matt Davidson Chief Development Officer, Director | Jun 12, 2026 | Award | +232,417 | – | – | 297,491 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +61,647 | – | – | 61,647 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +1,822.13 | – | – | 1,822 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +101.3 | – | – | 1,923 |
| Matt Davidson Chief Development Officer, Director | Jun 11, 2026 | Award | +3,427 | – | – | 3,427 |
| Tony Goodman Chief Operating Officer, Director | Apr 7, 2026 | Award | +26,510 | – | – | 26,523 |
| Vinay Shah Chief Financial Officer | Apr 7, 2026 | Award | +17,325 | – | – | 17,325 |
| Kevin Schuyler Director | Apr 7, 2026 | Award | +9,185 | – | – | 9,213 |
| Cary J. Claiborne Chief Executive Officer, Director | Apr 7, 2026 | Award | +37,985 | – | – | 40,417 |
| Robertson H. Gilliland Director | Apr 7, 2026 | Award | +9,185 | – | – | 9,185 |
| Kevin Schuyler Director | Sep 29, 2023 | Buy | +700 | $2.74 | $1.92K | 700 |
| William B. Stilley III Director | May 23, 2023 | Award | +240,800 | – | – | 1,261,779 |
| Joseph Truluck Chief Financial Officer | May 23, 2023 | Award | +157,500 | – | – | 265,139 |
| Cary J. Claiborne Chief Executive Officer, Director | May 23, 2023 | Award | +420,000 | – | – | 1,520,000 |
| William B. Stilley III Director | Dec 30, 2022 | Returned to company | −166,667 | – | – | 1,020,979 |
| Cary J. Claiborne Chief Executive Officer, Director | Sep 20, 2022 | Award | +75,000 | $0.42 | $31.50K | 1,100,000 |
| Cary J. Claiborne Chief Executive Officer, Director | Sep 19, 2022 | Award | +25,000 | $0.43 | $10.75K | 1,025,000 |
| Cary J. Claiborne Chief Executive Officer | Aug 18, 2022 | Award | +1,000,000 | – | – | 1,000,000 |
| William B. Stilley III Chief Executive Officer, Director | Feb 23, 2022 | Award | +250,000 | – | – | 1,187,646 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +10,000 | $2.71 | $27.10K | 34,644 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +5,000 | $2.72 | $13.60K | 50,221 |
| James W. Newman Jr. Director | Dec 30, 2021 | Buy | +10,000 | $2.66 | $26.60K | 20,000 |
| Kevin Schuyler Director, 10% owner | Dec 23, 2021 | Gift | −312,990 | – | – | 0 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Nov 30, 2021 | Buy | +10,600 | $2.75 | $29.15K | 937,646 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Nov 29, 2021 | Buy | +10,000 | $2.59 | $25.90K | 927,046 |
| James W. Newman Jr. Director | Nov 26, 2021 | Buy | +10,000 | $2.85 | $28.50K | 34,475 |
| Bankole A. Johnson Chief Medical Officer | Oct 4, 2021 | Sale | −200,000 | – | – | 148,246 |
| Bankole A. Johnson Chief Medical Officer | Apr 6, 2021 | Sale | −150,000 | $2.50 | $375.00K | 548,336 |
| James W. Newman Jr. Director | Jan 26, 2021 | Award | +1,187 | – | – | 14,475 |
| James W. Newman Jr. Director | Jan 26, 2021 | Award | +2,544 | – | – | 152,963 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Jan 26, 2021 | Award | +201,109 | – | – | 917,046 |
| Bankole A. Johnson Chief Medical Officer | Aug 20, 2020 | Sale | −350,000 | $1.21 | $423.50K | 1,055 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +5,000 | $1.42 | $7.10K | 15,000 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +4,644 | $1.35 | $6.27K | 14,644 |
| James W. Newman Jr. Director | Mar 27, 2020 | Buy | +10,000 | $1.34 | $13.40K | 13,288 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 26, 2020 | Buy | +12,652 | $1.47 | $18.60K | 715,937 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 25, 2020 | Buy | +12,348 | $1.13 | $13.95K | 703,285 |
| William B. Stilley III Chief Executive Officer, Director, 10% owner | Mar 3, 2020 | Award | +54,167 | – | – | 690,937 |
| Joseph Truluck Chief Financial Officer, Director | Mar 3, 2020 | Award | +27,084 | – | – | 107,639 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Dec 12, 2019 | Sale | −150,000 | $1.00 | $150.00K | 698,336 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Oct 2, 2019 | Award | +3,187 | – | – | 351,055 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +30,000 | $3.47 | $104.10K | 344,768 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +2,500 | $3.47 | $8.68K | 347,268 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 29, 2019 | Buy | +600 | $3.30 | $1.98K | 347,868 |
| Bankole A. Johnson Chief Medical Officer, 10% owner | Mar 28, 2019 | Buy | +40,000 | $3.15 | $126.00K | 314,768 |
| Kevin Schuyler Director | Jul 31, 2018 | Buy | +90,000 | – | – | 312,990 |
| Kevin Schuyler Director | Jul 31, 2018 | Other | +89,600 | – | – | 222,990 |
| Kevin Schuyler Director | Jul 31, 2018 | Other | +144,200 | – | – | 144,200 |
| Tony Goodman Director | Jul 31, 2018 | Buy | +7,000 | – | – | 8,755 |
| Joseph Truluck Chief Financial Officer | Jul 31, 2018 | Conversion | +5,927 | – | – | 80,555 |
| Robertson H. Gilliland Director | Jul 31, 2018 | Conversion | +29,931 | – | – | 95,424 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Adial Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?